- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03301675
Effect of Orange Juice and Healthy Diet on Cardiometabolic Risk Factors of Individuals With Metabolic Syndrome
March 30, 2023 updated by: Thais Cesar, São Paulo State University
Effect of Orange Juice Consumption Associated With Healthy Diet on Cardiometabolic Risk Factors of Individuals With Metabolic Syndrome
This study aimed to verify if combination of a healthy diet and orange juice consumption can minimize cardiometabolic risk factors for Metabolic Syndrome (MetS)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The clinical study was parallel, controlled, and randomized with metabolic syndrome subjects (ATPIII, AHA / NHLA) aimed at the consumption of an energy-balanced balanced diet for 12 weeks and divided into two groups: Control (n = 38): dietary guidance only; and Orange Juice (n = 38): diet guidance associated with 500 mL / day of 100% whole orange juice.
The recruitment process began in June 2016, the intervention was carried out from September 2016 to December 2016, and the data analysis started in January 2016.
The sample number took into account variances on LDL-C, with a type I error α = 0.05 and a type II error β = 0.2 (80% power).
The minimum sample size should have 32 individuals per group (n = 64).
Considering an approximately 15% dropout rate, the final sample size of study was constituted by 38 individuals per group.
Primary and secondary endpoints were the reduction of LDL-C and modification of the levels of cardiometabolic risk factors, inflammatory and hemodynamics parameters, respectively.
Kolmogorov Smirnov and Levene test assessed normality and homogeneity of data, respectively.
T-test was conducted to identify possible differences between OJ and control groups at baseline.
A linear mixed-effects model was apply to determine the time effect within and between groups (Sidak post hoc) and P significance was set up ≤ 0.05.
The assessment of body composition, metabolic biomarkers and food intake were analyzed over a 12-week intervention.
Study Type
Interventional
Enrollment (Actual)
76
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Three or more of the risk factors of MS: (1) waist circumference man ≥ 102 cm and woman ≥ 88 cm; (2) triglycerides ≥ 150 mg / dL; (3) HDL-C man ≤ 40 mg / dL and woman ≤ 50 mg / dL; (4) blood pressure ≥ 130 / ≥ 85 mm Hg and (5) fasting glucose ≥ 100 mg / dL (common diabetes, high blood pressure);
- 25 ≥ BMI ≤ 39.9 kg / m - overweight to grade II obesity;
- Like to consume orange juice;
Exclusion Criteria:
- Pregnant / nursing;
- Use of vitamins or vitamin-food supplements in the last three months;
- Individuals with diseases that require specific diet recommendations such as diabetes mellitus with insulin therapy and carbohydrate counts, cancer, chronic liver and kidney disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Orange juice
Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
|
Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight.
The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar).
Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
|
No Intervention: Control
Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL-C
Time Frame: 12 weeks
|
mg/dL
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total cholesterol
Time Frame: 12 weeks
|
mg/dL
|
12 weeks
|
HDL-C
Time Frame: 12 weeks
|
mg/dL
|
12 weeks
|
Glucose
Time Frame: 12 weeks
|
mg/dL
|
12 weeks
|
Triglycerides
Time Frame: 12 weeks
|
mg/dL
|
12 weeks
|
Waist circunference
Time Frame: 12 weeks
|
cm
|
12 weeks
|
Blood pressure systolic and diastolic
Time Frame: 12 weeks
|
mm Hg
|
12 weeks
|
Body lean mass
Time Frame: 12 weeks
|
kg
|
12 weeks
|
Body fat mass
Time Frame: 12 weeks
|
kg
|
12 weeks
|
Body fat
Time Frame: 12 weeks
|
percentage
|
12 weeks
|
Visceral fat area
Time Frame: 12 weeks
|
kg
|
12 weeks
|
Insulin
Time Frame: 12 weeks
|
µU/mL
|
12 weeks
|
hsCRP
Time Frame: 12 weeks
|
mg/dL
|
12 weeks
|
IL-6
Time Frame: 12 weeks
|
pg/ml
|
12 weeks
|
TNF-alfa
Time Frame: 12 weeks
|
pg/ml
|
12 weeks
|
ICAM
Time Frame: 12 weeks
|
ng/mL
|
12 weeks
|
VCAM
Time Frame: 12 weeks
|
ng/mL
|
12 weeks
|
Cardiovascular risk index
Time Frame: 12 weeks
|
% risk
|
12 weeks
|
Common carotid artery intima-media thickness - CCA-IMT
Time Frame: 12 weeks
|
mm
|
12 weeks
|
Pulse wave velocity - PWV
Time Frame: 12 weeks
|
cm/s
|
12 weeks
|
Flow-mediated dilatation of the brachial artery - BA-FMD
Time Frame: 12 weeks
|
percentage
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Thais B Cesar, Ph.D., Sao Paulo State University "Julio de Mesquita Filho", Faculdade de Ciências Farmacêuticas
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
May 1, 2017
Study Completion (Actual)
December 2, 2018
Study Registration Dates
First Submitted
September 25, 2017
First Submitted That Met QC Criteria
September 29, 2017
First Posted (Actual)
October 4, 2017
Study Record Updates
Last Update Posted (Actual)
April 3, 2023
Last Update Submitted That Met QC Criteria
March 30, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SaoPSU8
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Mayo ClinicCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Orange Juice (500 mL/d)
-
São Paulo State UniversityNational Association of Exporters of Citrus Juices; Citrosuco CompanyCompleted
-
Clinical Research Center Kiel GmbHNofimaCompleted
-
São Paulo State UniversityCompleted
-
PepsiCo Global R&DCompletedDigestive HealthUnited States
-
PepsiCo Global R&DCompletedGlycemic ResponseUnited States
-
Massachusetts General HospitalThe Beverage Institute for Health & WellnessCompleted
-
Loma Linda UniversityCompletedBlood PressureUnited States
-
University of ReadingCompleted
-
Quadram Institute BioscienceBiotechnology and Biological Sciences Research Council; European CommissionCompleted
-
Hasselt UniversityHochschule Geisenheim UniversityUnknown